PTPN11 encodes the Shp2 non-receptor protein-tyrosine phosphatase implicated in several signaling pathways. Activating mutations in Shp2 are commonly associated with juvenile myelomonocytic leukemia (JMML) but are not as well defined in other neoplasms. Here we report that Shp2 mutations occur in human acute myeloid leukemia (AML) at a rate of 6.6% (6/91) in the ECOG E1900 dataset. We examined the role of mutated Shp2 in leukemias harboring MLL translocations which co-occur in human AML. The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9 mediated leukemogenesis in vivo. Shp2E76K increased leukemic stem cell frequency and affords MLL-AF9 leukemic cells IL3 cytokine hypersensitivity. As Shp2 is reported to regulate anti-apoptotic genes, we investigated Bcl2, Bcl-xL and Mcl1 expression in MLL-AF9 leukemic cells with and without Shp2E76K.
Introduction
MLL rearrangements are present in ~20% of pediatric AML and can be as high as 80% of infant patients with ALL (1) and are generally associated with a poor outcome (2) . Rearrangements of the MLL locus generate potent oncogenic fusion proteins that retain the N-terminus of the MLL protein but replace the C-terminus with one of >60 different partner proteins that can recruit transcriptional activation complexes (3) (4) (5) (6) . The resultant deregulated transcriptional activation mediated by MLL fusion proteins blocks hematopoietic differentiation through the sustained expression of the posterior HOXA gene cluster, namely HOXA9 (7) . Interestingly, MLL leukemias display a relatively stable genome compared with other leukemic subtypes but still carry other genetic lesions at low frequency (8) . Type-I mutations involving the Ras pathway are present in about 37% of MLL rearranged leukemias including mutations within NRAS, KRAS, NF1 and PTPN11 (9) , consistent with the idea that pathological AML requires both type-I and type-II mutations (10) . Indeed, oncogenic NRAS G12V or FLT3-ITD can significantly accelerate MLL fusion protein mediated leukemogenesis in vivo (11) (12) (13) . Although these mutations strongly cooperate with MLL fusion proteins to promote leukemogenesis, little is understood about the molecular mechanisms utilized by type-I mutations.
PTPN11 encodes the ubiquitously expressed SHP2 non-receptor protein tyrosine phosphatase involved in the RAS, JAK-STAT, PI3K and other pathways (14, 15) . Mutations in PTPN11 are found in ~50% of patients with Noonan syndrome, as well as, ~37% of patients with hematologic malignancies such as juvenile myelomonocytic leukemia (JMML), ALL and AML (16) (17) (18) (19) . Recent genome-wide sequencing analyses have identified PTPN11 mutations in AML patients indicating this may function in a cooperative manner (20, 21). Shp2 positively regulates signal transduction pathways downstream of receptor tyrosine kinases, like Kit, where it is essential for hematopoietic stem and progenitor cells (22, 23) . Hematopoietic progenitors require Shp2 for STAT5 activation and upregulation of Mcl1 and Bcl-xL (24, 25) . In leukemia expression is often elevated and Shp2 can associate with FLT3-ITD leading to activation of STAT5. Shp2 co-localizes with STAT5 to activate expression of Bcl-xL protecting against cell death (26, 27) . PTPN11 mutations result in amino acid changes resulting in disrupted autoinhibition and hyperactive Shp2 enzymatic activity (17, (28) (29) (30) . Gain of function mutations in Shp2 result in cytokine hypersensitivity in hematopoietic progenitor cells (31). In mice, gain of function Shp2 mutations leads to a JMML-like fatal myeloproliferative disease whereas an inducible mutant Shp2 knock-in mouse model progresses to AML, as well as, B and T cell ALL with long disease latency (32-35). However, the molecular mechanisms leading to disease and the cooperative nature of hyperactive Shp2 with leukemic fusion proteins has not been explored.
To investigate whether mutations associated with PTPN11 can cooperate with oncogenic fusion proteins, we developed a mouse model of cooperative leukemogenesis with MLL-AF9 and the leukemia-associated Shp2E76K mutant that shows the highest basal phosphatase activity among all the disease-associated Shp2 mutations (17, 36) . Shp2E76K strongly cooperates with MLL-AF9 to accelerate leukemogenesis in mice by altering leukemic stem cell frequency. MLL-AF9 Shp2E76K cells display cytokine hypersensitivity and activation of the Erk pathway leading to upregulation of an anti-apoptotic gene program most prominently observed with Mcl1. We find that Shp2E76K expression in both mouse and human cells reduces MLL-AF9 sensitivity to chemical inhibition of Mcl1 suggesting mutant Shp2 cooperates mechanistically with MLL fusion proteins through Mcl1 expression.
Materials and Methods

Mice
Female C57BL/6 mice at 8 to 10 weeks old were purchased from Taconic Farms. B6.CgGt(ROSA)26Sortm1(rtTA*M2)Jae/J mice (TetOn mice) were purchased from Jackson laboratory. All animal studies were approved by the University of Michigan Committee on Use and Care of Animals and Unit for Laboratory Medicine.
Genetic analysis of primary patient AML samples
All primary patient samples came from pretreatment AML blood or bone marrow samples from patients treated on the ECOG E1900 clinical trial as previously described (37) . All patient samples were previously evaluated for cytogenetic abnormalities and sequenced for the following genes recurrently mutated in AML: ASXL1 , CEBPα, CKIT, DNMT3A, EZH2,  FLT3, NPM1, HRAS, IDH1, IDH2, KRAS, NRAS, PHF6, WT1, RUNX1, TET2 , and TP53 (37) . For sequencing of PTPN11, all coding regions of PTPN11 were amplified using RainDance microdroplet digital PCR enrichment (RainDance, Billerica, MA) as previously described (38, 39) followed by followed by Illumina HiSeq massively parallel sequencing. Primer sequences are available upon request.
Plasmids
MSCVpuro-Flag-mMcl1 plasmid was purchased from Addgene (32982). MSCVneo-Flag-MLL-AF9 and MSCVneo-E2A-HLF plasmids have been described before (40) . MIEG3 (retroviral vector utilizing the bi-cistronic MSCV backbone and expressing enhanced GFP) and MIEG3-Shp2E76K plasmids were provided by Dr. Rebecca Chan (Indiana University) (41) . shRNA plasmids were generated by inserting validated shRNA sequences into the XhoI and EcoRI sites of the pTRMPV-Hygro vector (42) . Mcl1 shRNAs and Renilla control shRNA sequences were described previously (43) . All shRNA sequences were listed in Supplementary Table 1 .
shRNA knockdown
Hematopoietic stem cells purified from TetOn mice were transformed with MLL-AF9 retrovirus. Freshly transformed (~2 weeks after transduction) cells were transduced with MIEG3 or MIEG3-Shp2E76K and sorted by GFP expression. GFP+ cells were transduced with Plat-E packaged shRNA retroviruses. Cells were selected with hygromycin for 1 week (140ug/ml for 5 days and 200μg/ml for 2 days) with fresh antibiotics added every 1 to 2 days. ShRNA containing cells were mixed with shRNA-none cells (i.e. TetOn MA9+MIEG3 or TetOn MA9+E76K) at 3:1 ratio and cultured in media containing 1μg/ml Doxcycline. 1 day after Doxcycline treatment, cells were harvested for flow cytometry to detect dsRed+ cell percentage in the mixed population. ShRNA knockdown after doxycycline treatment were verified by western blotting.
Chemical inhibition assay
All chemical inhibitors were dissolved in DMSO. Cells were cultured at 5×10 4 cells/ml in 12-well non-tissue culture plate in the presence of serially diluted Inhibitors. ABT-263 was added at 0.1, 0.33, 1, 2.5, 5μM. UMI-205, UMI-77, UMI-208, and UMI-212 were added at 1.25, 2.5, 5, 10, 20μM. DMSO was used as negative control. Cells were enumerated after 48 hours of culture and the growth rate k was calculated according to the exponential growth equation:
Additional methods can be found in Supplemental materials
Results
PTPN11 mutations functionally cooperate with specific oncogenes in AML
To gain insight into the mutational frequency of SHP2 in human AML, we sequenced PTPN11 by next-generation sequencing in 91 AML patients enrolled in the phase III clinical trial run by ECOG E1900 (47) . Six of 91 patients were identified to contain a mutation in PTPN11 resulting in a 6.6% mutational frequency in AML; consistent with a saturation analysis of cancer genes in AML (20) suggesting PTPN11 mutations are functionally important to leukemic transformation ( Table 1 ). All mutations were detected within exon 3 and resulted in amino acid changes previously associated with both AML and JMML (15, 17) . The E76K, T31I, E76Q, D61Y, F71L and E76G mutations all reside within an autoinhibitory region of the SHP2 protein and disrupts the N-SH2 interaction with the PTP domain leading to hyperactive phosphatase activity (16, 28) . PTPN11 mutations were found to co-occur with genetic alterations in DNMT3a, NPM1, WT1, CBF and MLL suggesting mutant SHP2 may cooperate functionally in AML. As PTPN11 mutations were previously reported in MLL associated leukemias (19), we tested whether hyperactive Shp2 can functionally cooperate with MLL fusion proteins in transformation. We performed primary bone marrow transduction and colony replating assays using retroviral vectors containing the oncogenic MSCV-MLL-AF9 (MA9) fusion protein and the hyperactive Shp2 mutant MIEG3-Shp2E76K (E76K) commonly associated with hematologic malignancies. While expression of E76K alone did not lead to significant replating potential indicative of cellular transformation, the E76K mutant significantly augmented MLL-AF9 mediated colony formation as evidenced by a two-fold increase in colony formation in the second round compared to MLL-AF9 and empty MIEG3 ( Figure 1A and B). Colony formation between MA9 and MA9+E76K was similar in tertiary plating that may reflect more efficient transformation or limitations in quantifying CFU potential in the absence of limiting dilutions. MA9 and MA9+E76K colonies were dense and composed of immature blast-like cells with a greater nuclear to cytoplasmic ratio compared to the diffuse colonies composed of macrophage type cells resulting from transduction with empty vectors or E76K alone ( Figure 1B) . Notably, while MLL-AF9 colonies were composed almost exclusively of primitive blast-like cells, MLL-AF9 and E76K co-transduced cells consistently contained sporadic differentiating macrophages ( Figure 1B) . To examine cooperation in other leukemic subtypes, we tested E76K expression in the presence of the unrelated leukemic oncoprotein E2A-HLF (EH) that transforms cells through an anti-apoptotic gene program, which is distinct from the HOX gene program used by MLL fusion proteins (48) . Interestingly, we did not observe a difference in E2A-HLF mediated colony replating capacity in the presence of E76K ( Figure 1A and B). Expression of Shp2E76K was confirmed by qPCR using Shp2 specific primer sets and RNA isolated after the first round of the colony assay ( Figure 1C ). Together, these data identify PTPN11 mutations as cooccurring with several common hematologic genetic alterations and functionally cooperating with MLL-AF9 mediated transformation in vitro.
Hyperactive Shp2 accelerates MLL-AF9 leukemia and alters leukemic stem cell frequency
We next assessed how Shp2 mutations affected MA9 mediated leukemogenesis in vivo.
Here we introduced either empty vectors, MSCV+E76K, MA9+MIEG3 or MA9+E76K into lin − c-kit + bone marrow cells by retroviral transduction. Cells were i.v. injected into lethally irradiated syngeneic recipients and allowed to engraft. Mice receiving cells transduced with empty vectors or MSCV+E76K did not show signs of disease through 150 days suggesting overexpression of E76K alone failed to induce a lethal leukemia (Figure 2A ). On the contrary, overexpression of E76K significantly accelerated MA9 mediated leukemogenesis resulting in decreased disease latency (p=0.0004, Log-Rank). The median survival of mice receiving MA9+MIEG3 cells (125 days) was more than double the median survival of mice receiving MA9+E76K (60 days) (Figure 2A ). Mice were monitored for 150 days with the first moribund MA9+E76K mouse euthanized on day 38 and the first MA9+MIEG3 mouse euthanized on day 103. MA9+MIEG3 or MA9+E76K mice displayed splenomegaly ( Figure  2B ) and compromised organ structure in the spleen and liver ( Figure 2C ). Histopathology revealed infiltrating leukemic blasts in the spleen and liver while bone marrow aspirates revealed blocked myeloid differentiation in diseased MA9 and MA9+E76K mice ( Figure  2C ). Overexpression of Shp2E76K was confirmed by western blotting splenocytes from MA9 and MA9+E76K diseased mice ( Figure 2D ). It is noteworthy that MA9+E76K mice with longer disease latencies also showed the lowest expression of Shp2 by western blot ( Figure 2D ). A correlation between Shp2E76K expression level and disease latency was established by plotting β-Actin normalized Shp2 protein expression levels against disease latency (R 2 = 0.90367) ( Figure 2D ). Overexpression of Ptpn11 was also confirmed by qPCR using cDNA from diseased splenocytes ( Figure 2E ). Remarkably, we did not detect a difference in the expression of the direct MLL-AF9 target genes Hoxa9 and Meis1 suggesting the difference in disease latency is not due to a change in the MLL-AF9 gene program induced by Shp2E76K ( Figure 2E ). To follow up on the difference in cell morphology observed in colony assays with MA9 or MA9+E76K ( Figure 1B ), we performed flow cytometry on splenocytes. Cell surface expression of Sca1 and c-kit was similar in both MA9 and MA9+E76K cells ( Figure 2F ). However, expression of both Cd11b and Gr1 were significantly higher in MA9+E76K cells compared to MA9 cells, consistent with a slightly more differentiated phenotype ( Figure 2F ). These data are consistent with a role of Shp2 in promoting hematopoietic differentiation through dephosphorylation of Runx1 (49) . To understand if accelerated leukemogenesis in the presence of E76K was due to altered leukemic stem cell (LSC) frequency, we performed a limiting dilution assay with primary leukemic cells isolated from MA9 and MA9+E76K diseased mice. These were injected into secondary recipients following sublethal irradiation and monitored for 109 days for disease. While MA9 cells displayed an LSC frequency of ~1 in 285, the presence of E76K significantly increased LSC frequency to ~1 in 50 ( Figure 2G ). These data suggest Shp2E76K cooperates with the MLL-AF9 fusion protein in vivo to accelerate leukemogenesis by altering LSC frequency.
Shp2E76K affords MLL-AF9 cells cytokine hypersensitivity
To investigate the mechanism of accelerated leukemogenesis, we generated cell lines with MA9 or MA9+E76K by retroviral transduction of lin − c-kit + bone marrow cells. We enriched for cells transduced with empty MIEG3 or E76K by sorting for GFP, which revealed an expansion of bone marrow cells expressing E76K that was evident four days after transduction (Supplementary Figure 1) . Proliferation assays demonstrated the E76K mediated bone marrow expansion was transient except in the presence of MLL-AF9 which initiated leukemic transformation ( Figure 3A ). Overexpression of mutant Shp2 was confirmed by western blot ( Figure 3B ). Previous studies had implicated hyperactive Shp2 in hematopoietic progenitor cell cytokine hypersensitivity (31, 41). We tested this in the context of MLL-AF9 leukemic cells by performing an IL3 withdrawal and proliferation assay. We observed increased tolerance for IL3 withdrawal in MA9+E76K cells compared to MA9 ( Figure 3C ). This was also accompanied by increased Erk phosphorylation in the absence of IL3. MA9+E76K cells displayed higher resting levels of Erk phosphorylation with limiting amounts of IL3 and showed greater Erk phosphorylation in response to IL3 compared to MA9 cells ( Figure 3D ).
Several studies have linked Shp2 activity with the upregulation of anti-apoptotic genes (24, 27). Thus, we examined expression of both the Bcl2 family of genes and direct MLL fusion targets by qPCR in MA9 and MA9+E76K cells to reveal the mechanism for Shp2E76K mediated accelerated leukemogenesis and cytokine hypersensitivity. We found the expression of Hoxa9 and Meis1 not significantly changed in the presence of Shp2E76K suggesting modulation of MLL targets genes is not responsible for cytokine hypersensitivity ( Figure 4A ). In contrast, we observed a significant upregulation of Bcl-xL and Mcl1 in MA9+E76K cells compared to MA9 cells in the presence of low dose IL3 (0.001ng/ml) ( Figure 4A ). The most significant increase was observed in Mcl1 mRNA expression with a ~4 fold upregulation, which was confirmed by western blot ( Figure 4B ). This is consistent with genetic analyses that identified Mcl1 as a key regulator of cell survival in MLL-ENL leukemic cells compared to Bcl2 or Bcl-xL (43) . Interestingly, there were only minor changes in Hoxa9, Mcl1, Bcl2 or Bcl-xL expression when Shp2E76K was over-expressed in normal lin− bone marrow suggesting a context dependent function for hyperactive Shp2 (Supplemental Figure 2) . While all anti-apoptotic genes were upregulated in the presence of Shp2E76K, Mcl1 clearly emerged as the most highly expressed and upregulated in MA9+E76K cells ( Figure 4A ). These data suggest that the Shp2E76K mutation may accelerate leukemogenesis through the upregulation of an anti-apoptotic gene program primarily mediated by Mcl1. Table 3 ). These data suggest MLL fusion protein transformed cells are less sensitive to Bcl2 inhibition compared to E2A-HLF cells and are consistent with previous work implicating Bcl2 in E2A-HLF mediated leukemic transformation (48) . On the contrary, MA9 cells were more sensitive to UMI-212 mediated Mcl1 inhibition compared to E2A-HLF cells ( Figure 6A ). The sensitivity of MA9 cells to UMI-212 was reduced with the addition of E76K such that the growth pattern was similar to E2A-HLF cells. These data are consistent with decreased cellular sensitivity to UMI-212 due to the upregulation of an anti-apoptotic Table 3 We next tested how a variety of human AML cells respond to Mcl1 inhibition. To this end, we sequenced several human AML cell lines to determine the mutational status of exon 3 of PTPN11. Among the cell lines tested, only U937 cells contained a PTPN11 mutation (G60R) (Supplemental Figure 5) . To determine how human leukemia cells containing a PTPN11 mutation would respond to anti-apoptotic protein inhibition, we treated the PTPN11 mutant U937 cell line and the PTPN11 wild type cell lines K562, Monomac6, THP-1 and ML2 with ABT-263, UMI-212 or UMI-205. While none of the cell lines showed a change in growth response to the control UMI-205 compound, U937 and THP1 cells were clearly more resistant to UMI-212 mediated Mcl1 inhibition compared to K562, MonoMac6 and ML2 cells ( Figure 7A ). U937 cells had an IC 50 Table 3 ). ML2 and THP1 cells showed slight sensitivity to ABT-263 mediated Bcl2/Bcl-xL inhibition ( Figure 7A ). These results were confirmed with additional Mcl1 specific inhibitors, which confirmed U937 desensitization to Mcl1 inhibition (Supplementary Figure 6) . While MCL1 expression varied between cell lines, colony forming ability generally decreased in a dose dependent fashion with MCL1 inhibition (Supplementary Figure 7A, B) . U937, K562 and THP1 cells displayed greater resistance to MCL1 inhibition compared to ML2 and MonoMac6 cells (Supplementary Figure 7A) . The increased resistance of THP1 and K562 cells along with U937 cells in proliferation and colony assays likely reflect the utility of multiple transformation mechanisms that may compensate for loss of MCL1. Of note, THP1 cells harbor activating mutations in NRAS that may contribute to increased MCL1 expression. Despite these cell lines carrying a variety of driver mutations, including CALM-AF10, BCR-ABL, MLL-AF9 and MLL-AF6, these data suggest that a Shp2 mutation in human AML cells may result in greater resistance to MCL1 inhibition.
Mcl1 expression recapitulates Shp2E76K mediated cellular effects
program, most notably Mcl1, by E76K. In addition, direct overexpression of Mcl1 in MA9+Mcl1 cells led to less sensitivity to UMI-212 similar to expression of E76K (Figure 6A, Supplementary Table 3). MA9 cells have an IC 50 of 5.197μM compared to 8.389μM, 8.711μM and 10.76μM for E2A-HLF, MA9+E76K and MA9+Mcl1 cells respectively (Supplementary
Discussion
Cooperative leukemia
Recent deep sequencing efforts have revealed a number of mutations that together with previously identified chromosomal abnormalities give a clearer picture of the genetic landscape of acute leukemias. The data presented currently provides an experimental validation of the premise proposed by Gilliland and others that complete leukemogenesis require mutations conferring a block in differentiation and promoting cell survival (10) . Although mouse models of both MLL-AF9 and Shp2E76K result in lethal leukemias (35, 53, 54), the long latencies of these diseases suggest cooperating events contribute to the disease. The presence of an MLL fusion protein, like MLL-AF9, leads to a block in hematopoietic differentiation through the sustained expression of Hoxa9 and Meis1. The addition of PTPN11 gain of function mutations lead to functional cooperation between the MLL-AF9 fusion protein and mutated Shp2 that results in significantly accelerated leukemogenesis by increasing LSC frequency through upregulation of an anti-apoptotic gene program that primarily includes Mcl1 ( Figure 7B ). Upregulation of the Bcl2 family, namely Mcl1, induced by activating mutations in Shp2, leads to decreased sensitivity of both murine and human leukemia cell lines to Mcl1 inhibitors, suggesting that patients harboring PTPN11 mutations (or others within the Ras pathway) may show a poorer response to Mcl1 inhibition than patients without. Our data also suggest that the signaling pathways linking Shp2E76K and Mcl1 overexpression may represent candidates for therapeutic targeting in combination with Mcl1 inhibitors.
Mcl1 is associated with transformation and modulated by cooperating mutations
Elegant genetic studies have clearly demonstrated the importance of an anti-apoptotic gene program in AML cells using both overexpression and gene depletion techniques. 
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Refer to Web version on PubMed Central for supplementary material. Table 1 PTPN11 mutations associated with leukemia patients from the phase III clinical trial run by ECOG E1900 (47). 
